In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Antimicrob Agents Chemother. 2019 Oct 22;63(11):e01692-19. doi: 10.1128/AAC.01692-19. Print 2019 Nov.


Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin, caspofungin, or micafungin) by broth microdilution. Results for ibrexafungerp were compared with those for each echinocandin. Ibrexafungerp had good activity against all echinocandin-resistant C. glabrata isolates.

Keywords: Candida glabrata; FKS; SCY-078; antifungal; echinocandins; ibrexafungerp; resistance.